EFM
ARCT icon

E Fund Management’s Arcturus Therapeutics ARCT Stock Holding History

E Fund Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,400
Closed -$250K – 323
2024
Q1 		$250K Buy
+7,400
New +$262K 0.02% 300
2023
Q3 		– Sell
-8,523
Closed -$244K – 295
2023
Q2 		$244K Sell
8,523
-550
-6% -$15K 0.02% 250
2023
Q1 		$217K Buy
+9,073
New +$163K 0.02% 283
2022
Q4 		– Sell
-12,713
Closed -$188K – 337
2022
Q3 		$188K Sell
12,713
-1,022
-7% -$17.1K 0.02% 311
2022
Q2 		$216K Buy
13,735
+1,825
+15% +$35.8K 0.02% 288
2022
Q1 		$321K Buy
+11,910
New +$304K 0.01% 179

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

E Fund Management's ARCT Position: Q2 2024 in Review

E Fund Management sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 7,400 shares — an estimated $250K sold.

E Fund Management first reported a position in ARCT in Q1 2022 and held it in 6 quarters. The position peaked at $321K in Q1 2022. 171 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • E Fund Management reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • E Fund Management sold 7,400 Arcturus Therapeutics shares in Q2 2024, an estimated $250K.
  • E Fund Management first reported a position in Arcturus Therapeutics in Q1 2022 and held it in 6 quarters.
  • E Fund Management's Arcturus Therapeutics position peaked at $321K in Q1 2022.
  • 171 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on E Fund Management's 13F filing for Q2 2024, filed 12 Aug 2024.